Xeloda® in the Treatment of Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|57|1|16-20

ISSN： 0030-2414

Source： Oncology, Vol.57, Iss.1, 1999-07, pp. : 16-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Topic: Capecitabine (Xeloda) for metastatic breast cancer

By  

Journal of Clinical Excellence, Vol. 4, Iss. 4, 2002-09 ,pp. : 425-428

Radcliffe Press

Access to resources Recommend Favorite

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 748-755

Karger

Access to resources Recommend Favorite

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

By  

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 330-337

Karger

Access to resources Recommend Favorite

Capecitabine for the oral treatment of metastatic breast cancer

By Cortés-Funes Hernán  

Women's Health, Vol. 2, Iss. 6, 2006-11 ,pp. : 805-817

Future Medicine

Access to resources Recommend Favorite

Prediction of Response to Hormonal Treatment in Metastatic Breast Cancer

By  

Oncology, Vol. 63, Iss. 4, 2002-11 ,pp. : 309-316

Karger

Access to resources Recommend Favorite